Home > Boards > US Listed > Biotechs > Portola Phramaceuticals (PTLA)

A couple of notes from the CC:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
H2R Member Profile
 
Followed By 13
Posts 1,422
Boards Moderated 0
Alias Born 07/17/14
160x600 placeholder
Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Re... PR Newswire (US) - 6/19/2019 11:05:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:43:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:37:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:34:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:27:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:20:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:16:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 4:49:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/5/2019 5:07:23 PM
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences GlobeNewswire Inc. - 5/28/2019 4:30:00 PM
Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® i... GlobeNewswire Inc. - 5/22/2019 10:45:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2019 8:38:16 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 8:07:58 AM
Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 5/8/2019 8:01:00 AM
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), t... GlobeNewswire Inc. - 4/26/2019 2:00:47 PM
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), t... GlobeNewswire Inc. - 4/26/2019 2:00:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/25/2019 11:21:27 AM
Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Developm... GlobeNewswire Inc. - 4/24/2019 8:30:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/22/2019 6:03:30 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/22/2019 6:03:24 AM
Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019 GlobeNewswire Inc. - 4/17/2019 4:15:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/16/2019 7:45:27 PM
New Research: Key Drivers of Growth for Newmont Mining, Johnson & Johnson, Portola Pharmaceuticals, MedEquities Realty Trust,... GlobeNewswire Inc. - 4/10/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/8/2019 7:04:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/1/2019 7:28:43 PM
H2R   Thursday, 11/08/18 12:10:24 PM
Re: None
Post # of 178 
A couple of notes from the CC:

On Finances:

"Importantly, as a result of our change in focus to prioritize Andexxa, we've been able to extend our cash runway into the first half of 2020."


On Andexxa adoption:

" We estimate that more than 4 million people in the United States are currently taking a Factor Xa inhibitor, and we expect that number to continue to grow at strong double-digit rates."

"We believe the success we are having in getting formulary approvals, orders and reorders is setting us up nicely for the anticipated launch of Gen 2 in early 2019."

"While our focus is on the Andexxa U.S. market, we continue to assess our European launch strategy as we approach the CHMP opinion date."

On PAS:

"we are on track for the December 31, 2018 PDUFA data for the anticipated approval of our Andexxa Gen 2 manufacturing process. In fact, we just received notification from the FDA that the PAS was deemed okay to file."

From the Q&A on targets:

" The tier 1 or our first set of targets are about 600 U.S. hospitals are Level I or Level II trauma centers or have Comprehensive Stroke designation. So those are the biggest institutions across the country. The next tier of about 900 additional accounts, additional hospitals were the Advanced Stroke Center designation."

Overall a very good CC in my opinion.

It will take time for the PPS to move, but it will move once revenue start pouring in.







Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist